<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823247</url>
  </required_header>
  <id_info>
    <org_study_id>M-14745-47</org_study_id>
    <nct_id>NCT04823247</nct_id>
  </id_info>
  <brief_title>Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study</brief_title>
  <acronym>POSITIVE</acronym>
  <official_title>A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective&#xD;
      observational study. The main purpose of this study is to assess the effect of tildrakizumab&#xD;
      on the overall wellbeing in patients with moderate-to-severe psoriasis using the 5-item World&#xD;
      Health Organization Wellbeing Index (WHO-5) questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Change From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Physician's Satisfaction Questionnaire Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in FamilyPso Questionnaire Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index-Relevant (DLQI-R) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Treatment-related Patient Benefit Index 2.0 (PBI 2.0) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Manifestations Distribution (Patient's Grid/Heat Map)</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Numerical Rating Scale (NRS) Scores for Itch, Pain, Joint Pain and Fatigue</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>Baseline; 16 and 28 weeks; 12, 18 and 24 months after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Compliance to Sociodemographic Characteristics and Clinical Characteristics</measure>
    <time_frame>From Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>From Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Tildrakizumab</arm_group_label>
    <description>Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tildrakizumab</intervention_name>
    <description>As provided in real world clinical practice.</description>
    <arm_group_label>Tildrakizumab</arm_group_label>
    <other_name>IL-23p19 inhibitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients with moderate-to-severe plaque psoriasis who need&#xD;
        systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor treatment in&#xD;
        real-world clinical practice.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with diagnosis of moderate-to-severe chronic plaque psoriasis documented in&#xD;
             the medical chart.&#xD;
&#xD;
          -  Patient who need systemic biologic therapy and qualify for treatment with an IL-23p19&#xD;
             inhibitor. Tildrakizumab must be the anti-IL-23p19 selected therapy before including&#xD;
             the patient in the study.&#xD;
&#xD;
          -  Patient aged 18 years or older at the time of patient recruitment.&#xD;
&#xD;
          -  Patient who have provided written informed consent (if required by country&#xD;
             regulations).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to comply with the requirements of the study (fulfilling of the study&#xD;
             questionnaires) or who, in the opinion of the study physician, should not participate&#xD;
             in the study.&#xD;
&#xD;
          -  Patients included in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ãˆric Massana</last_name>
    <phone>0034 932 913 986</phone>
    <email>eric.massana@almirall.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate-to-severe plaque psoriasis</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Tildrakizumab</keyword>
  <keyword>Prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-23</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

